ARS Pharmaceuticals, Inc. Operating Lease, Payments
ARS Pharmaceuticals, Inc. (SPRY) reported Operating Lease, Payments of $141.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2025-11-10
- ARS Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2025-09-30 was $141.00K, a 127.42% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2025-06-30 was $63.00K, a 3.28% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2025-03-31 was $63.00K, a 3.28% increase year-over-year.
- ARS Pharmaceuticals, Inc. operating lease, payments for the quarter ending 2024-09-30 was $62.00K.
- ARS Pharmaceuticals, Inc. operating lease, payments for fiscal 2021 was $1.84M, a 15.71% increase from fiscal 2020.
- ARS Pharmaceuticals, Inc. operating lease, payments for fiscal 2020 was $1.59M.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2025-09-30 | $141.00K 10-Q · filed 2025-11-10 | $204.00K derived: sum of 2 quarters · filed 2025-11-10 | $267.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $63.00K 10-Q · filed 2025-08-13 | $126.00K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $63.00K 10-Q · filed 2025-05-14 | |||
| 2024-09-30 | $62.00K 10-Q · filed 2025-11-10 | $123.00K derived: sum of 2 quarters · filed 2025-11-10 | $184.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $61.00K 10-Q · filed 2025-08-13 | $122.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $61.00K 10-Q · filed 2025-05-14 | |||
| 2022-09-30 | $458.00K 10-Q · filed 2022-11-02 | $961.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.48M 10-Q · filed 2022-11-02 | $1.99M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $503.00K 10-Q · filed 2022-08-11 | $1.02M 10-Q · filed 2022-08-11 | $1.53M derived: sum of 3 quarters · filed 2022-08-11 | $2.03M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $518.00K 10-Q · filed 2022-05-12 | $1.03M derived: sum of 2 quarters · filed 2022-05-12 | $1.52M derived: sum of 3 quarters · filed 2022-11-02 | $1.94M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $508.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.01M derived: sum of 2 quarters · filed 2022-11-02 | $1.42M derived: sum of 3 quarters · filed 2022-11-02 | $1.84M 10-K · filed 2022-03-31 |
| 2021-09-30 | $499.00K 10-Q · filed 2022-11-02 | $912.00K derived: sum of 2 quarters · filed 2022-11-02 | $1.33M 10-Q · filed 2022-11-02 | $1.74M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $413.00K 10-Q · filed 2022-08-11 | $834.00K 10-Q · filed 2022-08-11 | $1.24M derived: sum of 3 quarters · filed 2022-08-11 | $1.64M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $421.00K 10-Q · filed 2022-05-12 | $829.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.23M derived: sum of 3 quarters · filed 2022-05-12 | $1.61M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $804.00K derived: sum of 2 quarters · filed 2022-03-31 | $1.19M derived: sum of 3 quarters · filed 2022-03-31 | $1.59M 10-K · filed 2022-03-31 |
| 2020-09-30 | $396.00K 10-Q · filed 2021-11-10 | $785.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.18M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $389.00K 10-Q · filed 2021-08-12 | $786.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $397.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |